Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (28 quarters reported)
$113M in Q4 2015 → $37.9M now. Hover for any quarter.
As reported for the quarter ended September 30, 2022. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Ascendis Pharma A/s | 36.4% | Unchanged | 133,691 | $13.8M |
| Verona Pharma Plc. | 30.0% | Unchanged | 1,111,112 | $11.4M |
| Natera, Inc. | 18.4% | Unchanged | 159,160 | $6.97M |
| Cymabay Therapeutics, Inc. | 15.2% | Unchanged | 1,641,804 | $5.75M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2022 · filed November 14, 2022
No position changes this quarter.
quarter ended June 30, 2022 · filed August 12, 2022
No position changes this quarter.
quarter ended March 31, 2022 · filed May 13, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Natera, Inc. | Added | +68,160 | +$2.77M | 19.7% |
quarter ended December 31, 2021 · filed February 11, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | Exited | −1,954,904 | −$35.2M | — |
| AP Acceleron Pharma Inc. | Exited | −108,630 | −$18.7M | — |
| Ascendis Pharma A/s | New | +133,691 | +$18M | 45.5% |
| Natera, Inc. | New | +91,000 | +$8.5M | 21.5% |
| E Epizyme, Inc. | Exited | −998,278 | −$5.11M | — |
| Novavax, Inc. | Exited | −5,000 | −$1.04M | — |
quarter ended September 30, 2021 · filed November 12, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Natera, Inc. | Exited | −127,305 | −$14.5M | — |
| F Fibrogen, Inc. | Exited | −305,784 | −$8.14M | — |
quarter ended June 30, 2021 · filed August 16, 2021
No position changes this quarter.
quarter ended March 31, 2021 · filed May 17, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Oric Pharmaceuticals, Inc. | Exited | −496,893 | −$16.8M | — |
| Verona Pharma Plc. | New | +1,111,112 | +$9.29M | 8.2% |
| Aclaris Therapeutics, Inc. | Added | +334,660 | +$8.43M | 43.3% |
quarter ended December 31, 2020 · filed February 16, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| M Myokardia, Inc. | Exited | −399,360 | −$54.4M | — |
| Natera, Inc. | Trimmed | −81,463 | −$8.11M | 14.7% |
| Verona Pharma PLC | Exited | −1,111,112 | −$6.93M | — |
| Aclaris Therapeutics, Inc. | Added | +935,332 | +$6.05M | 12.2% |
| F Fibrogen, Inc. | Added | +133,284 | +$4.94M | 13.2% |
Loading...
